Abstract

Membranous nephropathy is a common cause of primary nephrotic syndrome, yet it can be particularly vexing to treat due to its extended duration and uncertainties about the implications of a partial remission. Ten years ago, the phospholipase A2 receptor (PLA2R) was identified as the major target

Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call